This open-label, single arm study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks, alone or in combination with standard anti-rheumatic therapy, for 12 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT02010216?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
